Drugs / TriPRIL CAR T Cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05020444 | Oct 2021 → Feb 2028 expected | plasma cell myeloma | Massachusetts General Hospital | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TriPRIL CAR T Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05020444 ↗ |
| Action | Deplete | “uses a person's own immune cells, called T cells, to try to kill their cancerous cells” NCT05020444 ↗ |
| Modality | Cell therapy | “TriPRIL CAR T Cells is an investigational treatment that uses a person's own immune cells, called T cells” NCT05020444 ↗ |
| Route | Intravenous | “Intravenous infusion” NCT05020444 ↗ |